Dr. Zane Martin is Program Director for Alzheimer’s Disease and Related Dementias Translational Research in the Division of Neuroscience at the National Institute on Aging (NIA). She oversees SBIR and STTR grants focused on drug discovery, drug development, and clinical trials aimed to ameliorate various dementias of aging.
Before being hired as Program Director, Zane was a AAAS Science & Technology Policy Fellow at NIA. During that time, she was awarded the National Institutes of Health Award of Merit for the development and implementation of the Alzheimer’s Disease Preclinical Efficacy Database (AlzPED). AlzPED is a publicly available data resource that aims to increase reproducibility, transparency, and translatability of preclinical Alzheimer’s drug discovery studies with the goal of improving the drug pipeline to human clinical trials.
Zane also completed a Christine Mirzayan Science & Technology Policy Fellowship at the National Academy of Sciences working in the Division on Earth and Life Studies where she explored perspectives on scientific engagement to improve public conversation about controversial topics in science, and she co-wrote the Public Engagement on Genetically Modified Organisms: When Science and Citizens Connect: Workshop Summary.
Dr. Martin has a Ph.D. in Neuroscience and M.S. in Pharmacology from the University of Texas Medical Branch. She received postdoctoral training in the Department of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities. Her research career has primarily focused on drug discovery strategies to combat Alzheimer’s disease and related dementias. She has investigated a wide range of therapeutic targets, including tau hyperphosphorylation, synaptic dysfunction, and amyloid aggregation.